Colorectal cancer(CRC)is one of the most common malignancies worldwide.Development of predictivemolecular markers may help to achieve the best outcome in clinic.The purpose of this study is to identify thedifferential...Colorectal cancer(CRC)is one of the most common malignancies worldwide.Development of predictivemolecular markers may help to achieve the best outcome in clinic.The purpose of this study is to identify thedifferentially expressed genes and new potential predictive and prognostic molecular biomarkers for CRC.Inthis study,CRC and matched normal tissues acquired from the same patient were used to extract total RNA.The NanoString nCounter assay was applied to determine the differentially expressed genes.The results werethen validated by using the Cancer Genome Atlas data.Finally,we identified 27 genes that revealed significantcorrelation with CRC in the tumor tissue.Several genes in the pan-cancer panel showed significant differentialexpression,which were more universal than others in the CRC tissue.Since some of them have not been reportedas being directly related to CRC yet,future mechanism studies can be designed based on this study.Our studydemonstrated NanoString nCounter assay could serve as an alternative approach for gene expression analysis andidentified several unreported differently expressed genes in CRC patients,which may provide some importantclues for more in-depth study of CRC and serve as potential predictive molecular biomarkers for clinical diagnosisapplication.展开更多
目的:探讨浸润性乳腺癌组织中HER2与Ki67的表达与蒽环类化疗药物疗效及临床预后的相关性。方法:数据库预测HER2基因在浸润性乳腺癌组织中的表达情况及与Ki67的关联性分析;利用Nanostring n Counter技术检测53例浸润性乳腺癌石蜡包埋组...目的:探讨浸润性乳腺癌组织中HER2与Ki67的表达与蒽环类化疗药物疗效及临床预后的相关性。方法:数据库预测HER2基因在浸润性乳腺癌组织中的表达情况及与Ki67的关联性分析;利用Nanostring n Counter技术检测53例浸润性乳腺癌石蜡包埋组织标本中HER2的mRNA表达情况,并分析蒽环类化疗药物的疗效;收集2008—2012年浸润性乳腺癌的组织蜡块222例,免疫组织化学方法检测HER2与Ki67的蛋白表达情况,并结合临床病理资料、化疗疗效及预后情况进行相关性分析。结果:GEPIA数据库分析显示HER2 mRNA在浸润性乳腺癌组织中的表达和Ki67的表达具有相关性;Nanostring nCounter技术检测53例浸润性乳腺癌组织中HER2 mRNA的表达水平,阳性16/53(30.19%),阴性为37/53(69.81%),HER2阳性患者中3例化疗有效(18.80%),13例无效(81.20%),HER2阴性患者中19例(51.35%)有效,18例(48.65%)无效;222例浸润性乳腺癌临床病理资料结果显示,HER2^(-)/Ki67^(+)浸润性乳腺癌患者有较好的化疗疗效和预后。结论:HER2阴性浸润性乳腺癌患者中,Ki67高表达预示有较好的化疗疗效,HER2^(-)/Ki67^(+)的浸润性乳腺癌患者预示有较好的生存期。展开更多
Many gene fusions have been recognized as important diagnostic and/or prognostic markers in human malignancies.In recent years,novel gene fusions have been identified in cases without prior knowledge of the genetic ba...Many gene fusions have been recognized as important diagnostic and/or prognostic markers in human malignancies.In recent years,novel gene fusions have been identified in cases without prior knowledge of the genetic background.Accompanied by a powerful computational data analysis method,new genome-wide screening approaches were used to detect cryptic genomic aberrations.This review focused on advanced genome-wide screening approaches in fusion gene identification,such as microarray-based approaches,next-generation sequencing,and NanoString nCounter gene expression system.The fundamental rationale and strategy for fusion gene identification using each biotech platform are also discussed.展开更多
基金the Natural Science Foundationof Shanghai(No.19ZR1476100)the Interdisciplinary Program of Shanghai Jiao Tong University(Nos.YG2019GD02,YG2019QNB23,YG2019QNA49 and YG2019QNA52)。
文摘Colorectal cancer(CRC)is one of the most common malignancies worldwide.Development of predictivemolecular markers may help to achieve the best outcome in clinic.The purpose of this study is to identify thedifferentially expressed genes and new potential predictive and prognostic molecular biomarkers for CRC.Inthis study,CRC and matched normal tissues acquired from the same patient were used to extract total RNA.The NanoString nCounter assay was applied to determine the differentially expressed genes.The results werethen validated by using the Cancer Genome Atlas data.Finally,we identified 27 genes that revealed significantcorrelation with CRC in the tumor tissue.Several genes in the pan-cancer panel showed significant differentialexpression,which were more universal than others in the CRC tissue.Since some of them have not been reportedas being directly related to CRC yet,future mechanism studies can be designed based on this study.Our studydemonstrated NanoString nCounter assay could serve as an alternative approach for gene expression analysis andidentified several unreported differently expressed genes in CRC patients,which may provide some importantclues for more in-depth study of CRC and serve as potential predictive molecular biomarkers for clinical diagnosisapplication.
文摘Many gene fusions have been recognized as important diagnostic and/or prognostic markers in human malignancies.In recent years,novel gene fusions have been identified in cases without prior knowledge of the genetic background.Accompanied by a powerful computational data analysis method,new genome-wide screening approaches were used to detect cryptic genomic aberrations.This review focused on advanced genome-wide screening approaches in fusion gene identification,such as microarray-based approaches,next-generation sequencing,and NanoString nCounter gene expression system.The fundamental rationale and strategy for fusion gene identification using each biotech platform are also discussed.
